Fig 1: Overexpression of kinesin family member 20B (KIF20B) in hepatocellular carcinoma (HCC) samples. A, Representative pictures of KIF20B immunohistochemical staining on clinical samples. B, H-score of KIF20B for different groups; presented as mean + SD. C, mRNA levels of KIF20B in HCC and para-HCC tissues (data from The Cancer Genome Atlas [TCGA]). D, Overall (left panel) and disease-free (right panel) survival rates of HCC patients with high KIF20B expression levels (red) and low levels (blue) (the cut-off for determining high vs low levels of KIF20B is the midpoint, data from TCGA). (*P < .05, ***P < .001)
Fig 2: The KIF20B knockdown inhibits pancreatic xenograft growth in vivo. (a) The tumor growth-curve of tumor volume according to time in control or knockdown groups (left). Representative picture of tumor in 29 days (right). n = 5. (b) KIF20B protein expression in xenograft tumor. (c) KIF20B protein expression was detected using immunohistochemistry. Representative pictures of immunohistochemistry in xenograft tumor (up). Quantification of expression in xenograft tumor (down). Student's t-test (*P < 0.05).
Fig 3: KIF20B knockdown via lentivirus‐mediated shRNA in different human pancreatic cancer cell lines. (a) QPCR was conducted on control cell and knockdown cell for KIF20B mRNA expression in PANC-1 and BxPC-3 cell lines. (b) Protein expression was detected using western blotting in control cell and KIF20B knockdown cell (up: representative image of western blotting; down: quantification of KIF20B). Student's t-test (∗P < 0.05).
Fig 4: Adenoviral vector expressing small hairpin RNAs targeting kinesin family member 20B (Ad-shKIF20B) enhances taxol toxicity to hepatocellular carcinoma cells. A, Quantification of KIF20B mRNA levels in HepG2, Hep3B and HuH-7 cells 48 h after infection. MOI = 1. B, Relative cell viability of HepG2, Hep3B and HuH-7 cells by MTT assays 72 h after indicated treatments. C, Relative cell viability of HepG2, Hep3B and HuH-7 cells with indicated treatments by MTT assays. MOI = 1, taxol concentration = 1 µmol/L. B,C, Value of control group was arbitrarily set at 1. Three independent experiments were carried out. D, Colony formation assays with indicated treatments. MOI = 1, taxol concentration = 1 µmol/L. E, MTT assays were carried out after cells received adenoviral vector expressing shRNAs targeting KIF20B (Ad-shKIF20B) and taxol for 72 h. Standard isobolograms are shown. IC 50 values for each drug are plotted on the axes; the solid line represents the additive effect, whereas the points represent the concentrations of each drug resulting in 50% inhibition of proliferation. Points falling below the line indicate synergism, whereas those above the line indicate antagonism
Fig 5: High expression of KIF20B is negatively correlated with prognosis in pancreatic cancer. (a) KIF20B overexpression in pancreatic cancer in GEO database. (b) Disease-free survival from GEO database with different expression levels of KIF20B. (c) Overall survival from GEO database. Student's t test (*P < 0.05).
Supplier Page from Abcam for Anti-MPP1 antibody